Livostin - General Information
Livostin is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Livostin was discovered at Janssen Pharmaceutica in 1979.
Pharmacology of Livostin
Livostin is a selective histamine H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils. Both histamine and antigens induced conjunctivitis can be inhibited by levocabastine. Livostin can also reduce symptoms of allergic rhinitis by preventing an increase in vascular permeability of nasal mucosa.
Livostin for patients
SHAKE WELL BEFORE USING.
To prevent contaminating the dropper tip and suspension, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. Do not use if the suspension has discolored. Store at controlled room temperature. Protect from freezing.
This product is contraindicated in persons with known or suspected hypersensitivity to any of its components. It should not be used while soft contact lenses are being worn.
Additional information about Livostin
Livostin Indication: As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. Also used as a nasal spray for allergic rhinitis.
Mechanism Of Action: Livostin is a potent, selective histamine H1-receptor antagonist. It works by competing with histamine for H1-receptor sites on effector cells. It thereby prevents, but does not reverse, responses mediated by histamine alone. Livostin does not block histamine release but, rather, prevents histamine binding and activity. Livostin also binds neurotensin 2 receptors and serves as a neurotensin agonist. This can induce some degree of analgesia.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Levocabastine
Synonyms: Levocabastina [Spanish]; Levocabastin; Levocabastinum [Latin]
Drug Category: Histamine H1 Antagonists
Drug Type: Small Molecule; Approved
Absorption: After instillation in the eye, levocabastine is systemically absorbed, albeit at low levels.
Toxicity (Overdose): Adverse effects include visual disturbances, dry mouth, cough, nausea, eyelid edema and lacrimation.
Protein Binding: Not Available
Biotransformation: Mostly unchanged. 10 to 20% is metabolized to the acylglucuronide of levocabastine.
Half Life: 36 hours (after oral administration)
Dosage Forms of Livostin: Solution / drops Ophthalmic
Chemical IUPAC Name: (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
Chemical Formula: C26H29FN2O2
Levocabastine on Wikipedia: https://en.wikipedia.org/wiki/Levocabastine
Organisms Affected: Humans and other mammals